92 related articles for article (PubMed ID: 27784671)
1. Somatic mosaicism in chronic myeloid leukemia in remission.
Mitani K; Nagata Y; Sasaki K; Yoshida K; Chiba K; Tanaka H; Shiraishi Y; Miyano S; Makishima H; Nakamura Y; Nakamura Y; Ichikawa M; Ogawa S
Blood; 2016 Dec; 128(24):2863-2866. PubMed ID: 27784671
[No Abstract] [Full Text] [Related]
2. Why chronic myeloid leukaemia cannot be cured by tyrosine kinase-inhibitors.
Baccarani M; Gale RP
Leukemia; 2021 Aug; 35(8):2199-2204. PubMed ID: 34002028
[No Abstract] [Full Text] [Related]
3. Comparative In vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia.
Laneuville P; Dilea C; Yin OQ; Woodman RC; Mestan J; Manley PW
J Clin Oncol; 2010 Apr; 28(11):e169-71; author reply e172. PubMed ID: 20194843
[No Abstract] [Full Text] [Related]
4. Exploring the curative potential of BCR-ABL1-targeting drugs for chronic myeloid leukaemia.
Valent P
Lancet Oncol; 2010 Nov; 11(11):1010-1. PubMed ID: 20965784
[No Abstract] [Full Text] [Related]
5. Response dynamics of pediatric patients with chronic myeloid leukemia on imatinib therapy.
Proschmann R; Baldow C; Rothe T; Suttorp M; Thiede C; Tauer JT; Müller MC; Hochhaus A; Roeder I; Glauche I
Haematologica; 2017 Feb; 102(2):e39-e42. PubMed ID: 27856510
[No Abstract] [Full Text] [Related]
6. The role of ponatinib in chronic myeloid leukemia in the era of treatment free remission.
Andrews C; Lipton J
Leuk Lymphoma; 2019 Dec; 60(13):3099-3101. PubMed ID: 31556337
[No Abstract] [Full Text] [Related]
7. Spectrum of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia from India with suspected resistance to imatinib-mutations are rare and have different distributions.
Markose P; Chendamarai E; Balasubramanian P; Velayudhan SR; Srivastava VM; Mathews V; George B; Viswabandya A; Srivastava A; Chandy M
Leuk Lymphoma; 2009 Dec; 50(12):2092-5. PubMed ID: 19925053
[No Abstract] [Full Text] [Related]
8. Chronic myelogenous leukemia. Preface.
DeAngelo DJ
Hematol Oncol Clin North Am; 2011 Oct; 25(5):ix-x. PubMed ID: 22054737
[No Abstract] [Full Text] [Related]
9. Reflexive Screening for BCR-ABL1 Kinase Domain Mutations in Chronic Myeloid Leukemia.
Langabeer SE; McCarron SL; Haslam K; Preston L
Clin Lab; 2016; 62(5):975-6. PubMed ID: 27349028
[No Abstract] [Full Text] [Related]
10. Chronic myeloid leukemia: Global impact from a local laboratory.
Radich JP
Cancer; 2017 Jul; 123(14):2594-2596. PubMed ID: 28586121
[No Abstract] [Full Text] [Related]
11. Monitoring of leukemia stem cells in chronic myeloid leukemia patients.
Cui J; Zhu Z; Liu S; Li Q; Meng L; Cheng H; Zhong Z; Li W; You Y; Zhu X; Zou P
Leuk Lymphoma; 2018 Sep; 59(9):2264-2266. PubMed ID: 29334838
[No Abstract] [Full Text] [Related]
12. The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors.
D'Adda M; Farina M; Schieppati F; Borlenghi E; Bottelli C; Cerqui E; Ferrari S; Gramegna D; Pagani C; Passi A; Maifredi A; Tucci A; Capucci MA; Ruggeri G; Rossi G
Cancer; 2019 May; 125(10):1674-1682. PubMed ID: 30707758
[TBL] [Abstract][Full Text] [Related]
13. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease.
Rousselot P; Charbonnier A; Cony-Makhoul P; Agape P; Nicolini FE; Varet B; Gardembas M; Etienne G; Réa D; Roy L; Escoffre-Barbe M; Guerci-Bresler A; Tulliez M; Prost S; Spentchian M; Cayuela JM; Reiffers J; Chomel JC; Turhan A; Guilhot J; Guilhot F; Mahon FX
J Clin Oncol; 2014 Feb; 32(5):424-30. PubMed ID: 24323036
[TBL] [Abstract][Full Text] [Related]
14. Ariad Pharmaceutical's ninja cancer drug inhibits armies of mutants.
Wolfson W
Chem Biol; 2012 Sep; 19(9):1075-6. PubMed ID: 22999871
[No Abstract] [Full Text] [Related]
15. Mechanisms of resistance to BCR-ABL TKIs and the therapeutic strategies: A review.
Yang K; Fu LW
Crit Rev Oncol Hematol; 2015 Mar; 93(3):277-92. PubMed ID: 25500000
[TBL] [Abstract][Full Text] [Related]
16. Treatment of an adolescent with chronic myeloid leukemia and the T315I mutation with ponatinib.
Nickel RS; Daves M; Keller F
Pediatr Blood Cancer; 2015 Nov; 62(11):2050-1. PubMed ID: 25939962
[No Abstract] [Full Text] [Related]
17. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
18. Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia.
Lin HX; Sjaarda J; Dyck J; Stringer R; Hillis C; Harvey M; Carter R; Ainsworth P; Leber B; Pare G; Sadikovic B
Eur J Haematol; 2016 Apr; 96(4):360-6. PubMed ID: 26059983
[TBL] [Abstract][Full Text] [Related]
19. Case with chronic myeloid leukemia and T315I mutation, but still in complete molecular response under high dose imatinib therapy.
Moro MI; Manrique G; Uriarte R; Díaz L
Leuk Lymphoma; 2014 Jul; 55(7):1684-6. PubMed ID: 24083818
[No Abstract] [Full Text] [Related]
20. Chronic myeloid leukemia: reaching for the cure.
Nencioni A; Cea M; Montecucco F; Gobbi M; Patrone F
Curr Cancer Drug Targets; 2013 Sep; 13(7):709-10. PubMed ID: 23957630
[No Abstract] [Full Text] [Related]
[Next] [New Search]
